High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...

A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...

a new golden child could be emerging in the form of Beyfortus. During its first full year on the market, the respiratory syncytial virus (RSV) antibody easily broke the $1 billion sales threshold.

The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. I keep a slim copy ...

More than 2 years after the child was born, no identifiable features of SMA have been observed, reported Richard Finkel, MD, of St. Jude Children's Research Hospital in Memphis, Tennessee, and ...

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.

Get Your Free Sample Market Report: What is behind the incessant drive of the beyfortus global market ? The increasing incidence of RSV cases continues to propel the market ahead. RSV is an ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Sanofi and partner AstraZeneca’s AZN RSV antibody Beyfortus (nirsevimab) recorded sales of €841 million in the fourth quarter, up 107% year over year, driven by higher sales in the United ...